Phase 2 Trial Examines Gene-Expression Profiling for Cancer of Unknown Primary Site

View original article HERE. A randomized phase 2 trial examining the assignment of treatment based on gene-expression profiling compared with standard chemotherapy for patients with cancer of unknown primary site showed no improvement in the 1-year survival rate with the more tailored approach. However, several caveats may limit the relevance of the findings. A report […]

Read More